What is Wedbush’s Estimate for Chimerix FY2028 Earnings?

Chimerix, Inc. (NASDAQ:CMRX) – Investment analysts at Wedbush raised their FY2028 earnings estimates for Chimerix in a research report issued to clients and investors on Tuesday, February 18th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn $0.58 per share for the year, up from their prior estimate of $0.47. Wedbush currently has a “Outperform” rating and a $7.00 price objective on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a report on Tuesday.

Chimerix Stock Up 5.2 %

CMRX stock opened at $5.08 on Wednesday. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $5.53. The firm’s 50-day simple moving average is $3.68 and its 200 day simple moving average is $1.90. The stock has a market cap of $456.90 million, a PE ratio of -5.40 and a beta of 0.35.

Insider Buying and Selling

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 20,760 shares of company stock valued at $91,175 in the last quarter. Company insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Chimerix

Large investors have recently made changes to their positions in the business. Bender Robert & Associates bought a new position in shares of Chimerix during the 4th quarter valued at about $37,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Chimerix in the fourth quarter worth about $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix in the fourth quarter worth about $62,000. Diadema Partners LP acquired a new position in shares of Chimerix in the fourth quarter worth about $101,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Chimerix in the fourth quarter worth about $130,000. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.